Investor News Archives - Inify Laboratories

Panel talk about Inify’s third quarter

Financial reports, Investor News, News 2022-11-09

The third quarter of 2022 saw progress in several areas, such as the construction of the laboratory facilities in Campus Solna in Stockholm, the setup of a simulation laboratory in Linköping and the recruitment of skilled personnel, including that of Dr. Claes Lindh, the company’s new Chief Medical Officer (CMO) as of September. Some highlights of […]

INIFY Laboratories – Laboratory and recruitment on track with positive market feedback

Financial reports, Investor News 2022-10-26

STOCKHOLM – October 26, 2022 Inify Laboratories, a fully integrated digital ultramodern laboratory services within pathology that provides cancer diagnostics, is advancing towards opening of the company’s new laboratory, situated on Campus Solna close to Karolinska Institutet in Stockholm. “In an impressively short time, we have built a simulation lab where we further improve, test […]

Inify Laboratories AB (publ) – Extraordinary General Meeting

Annual General Meeting, Investor News 2022-08-30

Stockholm, Sweden, August 30, 2022; Today, the 30th of August 2022, Inify Laboratories AB, org. no. 559345-4431, held an extraordinary general meeting in Stockholm. Total 31,807,064 shares were represented at the general meeting, which corresponds to 70.3% of the total shares and votes. The meeting decided, with the required majority, on all matters in accordance […]

Inify Laboratories – mandatory notification of trade

Investor News, Primary Insider Transactions 2022-08-19

Stockholm, Sweden, August 19, 2022 – Inify Laboratories AB (“Inify”) has been notified that the following transaction has been completed by a close associate to a primary insider in Inify: Monsun AS, a Norwegian company controlled by Magne Jordanger, board member and primary insider in Inify, has bought 336,950 shares in Inify at an average […]

Inify’s first ultramodern laboratory on track

Financial reports, Investor News, News 2022-08-17

STOCKHOLM – August 17 2022 – Inify Laboratories, a company providing fully digitalized pathology laboratory services for cancer diagnostics, listed in June 2022 on the Euronext Growth in Oslo, is on track in building its first ultramodern laboratory at Campus Solna, Sweden, next to world-leading healthcare. “We signed a five-year leasing contract for our office and […]

Notice to Extraordinary General Meeting in Inify Laboratories AB (publ)

Annual General Meeting, Investor News 2022-07-28

STOCKHOLM – July 28, 2022 – Inify Laboratories AB (publ) hereby invites its shareholders to en Extraordinary General Meeting on August 30th, 2022. Please find attached the invitation including agenda and details on how to register and vote. Please contact the companys CFO Ann-Charlotte Linderoth at e-mail: for any questions regarding the EGM.

Inify Laboratories announces the appointment of Chief Medical Officer (CMO)

Investor News 2022-06-29

Stockholm, June 29th 2022 Inify Laboratories announces the addition of specialized medical competence to the company’s management team and organization. “We warmly welcome Dr. Claes Lind to the role as CMO. His impressive background in clinical diagnostics and education fits us perfectly. He will play an instrumental role in our establishment and expansion phase. The […]

Inify Laboratories – now listed on Euronext Growth in Oslo under the INIFY ticker

Investor News 2022-06-20

“Today I’m truly thrilled to announce that Inify Laboratories is admitted to trading on Euronext Growth Oslo, less than 5 months after we became independent. With solid funding of NOK 150 million, provided through an equity issue towards supportive long-term shareholders as well as the management and Board of Directors, we have all prerequisites in […]

Inify Laboratories – Decision on admission to trading – Euronext Growth Oslo

Investor News 2022-06-16

Stockholm, June 16, 2022 Oslo Børs has decided to admit Inify Laboratories AB to trading. It is stipulated that the company prior to the first day of trading must satisfy the admission requirements on Euronext Growth Oslo. The first trading date on Euronext Growth Oslo is expected to take place on 20 June 2022. Company […]

Inify Laboratories – Extended subscription period

Investor News, News 2022-05-30

STOCKHOLM – May 30th, 2022 Inify Laboratories AB has decided to extend the Subscription Period in the ongoing Subsequent Offering to 3 June 2022 at 16:30 hours (CEST). As a consequence of this extension, the payment date will be on or about 8 June 2022 and delivery of shares will take place on or about […]